Gregory B. Lim

3 days ago | nature.com | Gregory B. Lim

In two clinical trials presented at the European Atherosclerosis Society Congress 2025, treatment with the cholesteryl ester transfer protein (CETP) inhibitor obicetrapib in addition to background lipid-lowering therapy significantly reduced plasma LDL-cholesterol (LDL-C) levels. A large, phase III clinical trial is ongoing to test the effects of obicetrapib on cardiovascular outcomes.

1 month ago | nature.com | Gregory B. Lim

Researchers have engineered a millimetre-scale, bioresorbable, optoelectronic system that can be minimally invasively implanted into the heart and wirelessly controlled by a light source on the surface of the skin to provide temporary cardiac pacing. The details have been published in Nature. Patients with short-lived bradycardia, such as after cardiac surgery or a myocardial infarction, can be treated with the temporary implantation of a pacemaker.

Feb 10, 2025 | nature.com | Gregory B. Lim

Tissue engineered heart muscle (EHM) implanted on to the epicardium can structurally and functionally remuscularize the failing hearts of rhesus macaques, with no major adverse effects. A clinical trial of this approach is now underway in patients with heart failure, and histological data from one participant show similar feasibility and signs of efficacy to the non-human primate model. These findings were published in Nature.

Sep 18, 2024 | nature.com | Gregory B. Lim

In patients who are undergoing transcatheter aortic valve implantation (TAVI) for severe aortic stenosis and who have stable coronary artery disease (CAD), percutaneous coronary intervention (PCI) reduces the occurrence of major adverse cardiac events compared with conservative treatment. This finding from the NOTION-3 trial was presented at the ESC Congress 2024. Aortic stenosis and CAD have shared risk factors, aetiology and clinical presentation.

Jul 22, 2024 | nature.com | Gregory B. Lim

Proteins in the sarcomere complex are stochastically removed and degraded and are replaced by newly translated proteins. Sarcomere turnover occurs at a similar rate within cardiomyocytes and across the heart and slows with ageing. These findings, published in Circulation Research, contrast with the prevailing ‘protein pool’ model of sarcomere turnover, in which sarcomeres were thought to be maintained by free recycling of proteins between the sarcomere and cytoplasmic pools of soluble proteins.